Illumina Inc (ILMN) 215.38 $ILMN
4 IBD 50 Stocks Poised To Bounce Back With Market
at Investor's Business Daily - Tue Jul 28, 3:13PM CDT
As the market bounces back after five straight sessions of losses, here's a look at four IBD 50 stocks that could bounce back after finding support at their moving averages: United Therapeutics (UTHR), Ellie Mae (ELLI), Epam Systems (EPAM) and...
ELLI: 70.65 (-0.96), UTHR: 165.31 (-0.65), ILMN: 215.38 (-2.44), EPAM: 74.46 (+1.78)
3 Signs That the Healthcare Stock Bubble Might Have Just Popped
George Budwell, The Motley Fool - Motley Fool - Mon Jul 27, 9:42AM CDT
Over the past five years or so, healthcare stocks have been absolutely trouncing the broader markets, leading many to call this unprecedented bull run a "bubble." A deeper look, though, reveals that most of this hypergrowth in the healthcare...
BIIB: 310.68 (-9.25), ILMN: 215.38 (-2.44), ABBV: 71.39 (+0.16)
Valeant, Starbucks Lead 5 IBD 50 Stocks Bucking Market
at Investor's Business Daily - Fri Jul 24, 6:14PM CDT
A handful of IBD 50 stocks got a boost last week, bucking overall market weakness, thanks to better-than-expected quarterly results. Illumina (ILMN), which makes genetic testing equipment, was among the few disappointments. It plunged 8% Wednesday...
VRX: 254.25 (-3.70), ELLI: 70.65 (-0.96), FB: 96.05 (+0.76), UHS: 141.69 (+0.32), UTHR: 165.31 (-0.65), ORLY: 239.78 (-1.17), EW: 151.25 (-4.55), ILMN: 215.38 (-2.44), MANH: 64.23 (-0.29), SBUX: 57.32 (+0.18), VDSI: 21.06 (-5.49), CRUS: 33.11 (-1.11), TASR: 31.18 (+0.40), AAPL: 122.67 (-0.71)
10.7% Return Seen to Date on SmarTrend Illumina Call (ILMN)
Comtex SmarTrend(R) - Wed Jul 22, 4:56PM CDT
SmarTrend identified an Uptrend for Illumina (NASDAQ:ILMN) on May 11th, 2015 at $196.42. In approximately 2 months, Illumina has returned 10.73% as of today's recent price of $217.49.
ILMN: 215.38 (-2.44)
Illumina Breaches Key Level On Q2 Sales Miss
at Investor's Business Daily - Wed Jul 22, 3:54PM CDT
Illumina (ILMN) surpassed second quarter earnings estimates late Tuesday but missed on revenue for the first time in six years. Analysts expected a beat-and-raise from the maker of gene sequencing systems, so its shares suffered in the stock market...
BIIB: 310.68 (-9.25), VRX: 254.25 (-3.70), DGX: 73.19 (+1.07), ILMN: 215.38 (-2.44), ABBV: 71.39 (+0.16), CELG: 132.79 (-2.63)
After Yesterday's Decline of 8.44%, Illumina Offers Investors Better Value
Comtex SmarTrend(R) - Wed Jul 22, 3:47PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $207.02 to a high of $220.00. Yesterday, the shares fell 8.4%, which took the trading range below the 3-day low of $230.00 on volume of 6.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 215.38 (-2.44)
Watch for Illumina to Potentially Rebound After Falling 8.44% Yesterday
Comtex SmarTrend(R) - Wed Jul 22, 3:47PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $207.02 to a high of $220.00. Yesterday, the shares fell 8.4%, which took the trading range below the 3-day low of $230.00 on volume of 6.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 215.38 (-2.44)
Apple and 3 Other Stocks with Major Price Changes Post-Earnings - Stocks in the News
Maher Syed - Zacks Investment Research - Wed Jul 22, 1:54PM CDT
The price reaction to each report is most volatile just after the earnings are announced. Trading the next day tends to bear some significant weight as well, though.
ISRG: 538.61 (-1.65), CMG: 737.72 (+6.94), ILMN: 215.38 (-2.44), AAPL: 122.67 (-0.71)
How to Trade 5 of the Market's Most Active Stocks
at The Street - Wed Jul 22, 1:40PM CDT
Here's a technical look at how to trade some of the highest-volume stocks on the market today.
KO: 40.60 (+0.05), XOM: 82.75 (+0.27), ILMN: 215.38 (-2.44), TSM: 21.92 (+0.04), MSFT: 46.72 (+1.38)
Comeback Efforts Lose Steam; Lithia Revs Higher
at Investor's Business Daily - Wed Jul 22, 11:03AM CDT
Stocks continued to trade in the red, with rebound efforts fading near Wednesday's halftime. The Nasdaq was off 0.8%, hurt by Apple (AAPL), which lost 5% on lighter-than-expected iPhone demand and a soft sales outlook. Intraday, the Nasdaq was down...
LAD: 117.34 (+4.75), ILMN: 215.38 (-2.44), MANH: 64.23 (-0.29), AAPL: 122.67 (-0.71), PII: 135.95 (-0.91)
Why Illumina Inc. Stock Sank Like a Stone Today
George Budwell, The Motley Fool - Motley Fool - Wed Jul 22, 10:58AM CDT
What's happening : Shares of the gene-sequencing company Illumina dropped by as much as 11% today on heavy volume following the release of its second-quarter results after the bell yesterday. For the quarter, Illumina posted $539 million in...
ILMN: 215.38 (-2.44)
Illumina (ILMN) Stock Falls After Reporting Earnings Results
at The Street - Wed Jul 22, 10:33AM CDT
Illumina (ILMN) shares are declining after the company reported its earnings results for the 2015 second quarter.
ILMN: 215.38 (-2.44)
Illumina Tops Q2 Earnings, Misses on Revenues; EPS View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 9:10AM CDT
Illumina's (ILMN) bottom line comfortably exceeded the Zacks Consensus Estimate, while the top line missed the same.
NLNK: 51.08 (-2.73), LGND: 104.20 (-1.64), ILMN: 215.38 (-2.44), AMAG: 64.83 (-1.40)
Downgrade Alert for Illumina (ILMN)
Comtex SmarTrend(R) - Wed Jul 22, 8:07AM CDT
Illumina (NASDAQ:ILMN) was downgraded from Buy to Neutral at Janney Montgomery today. The stock closed yesterday at $237.54 on volume of 2.3 million shares, above average daily volume of 1.3 million. In the past 52 weeks, shares of Illumina have traded between a low of $25.57 and a high of $242.37 and closed yesterday at $237.54, which is 829% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 1.3% while the 200-day MA has risen 0.6%.
ILMN: 215.38 (-2.44)
Stock Futures Down, Action Mixed; Apple, Vasco, Illumina Tumble
at Investor's Business Daily - Wed Jul 22, 8:04AM CDT
Stock futures veered unevenly lower on a heavy slate of earnings reports ahead of Wednesday's open. Dow futures were down 30.3 points below fair market value, but had pared early losses. Nasdaq 100 futures were down 62.4 points and sliding. S&P 500...
KO: 40.60 (+0.05), WHR: 178.17 (+1.45), VDSI: 21.06 (-5.49), SWKS: 94.07 (-1.61), ILMN: 215.38 (-2.44), CRUS: 33.11 (-1.11), HAWK: 44.53 (+0.41), MSFT: 46.72 (+1.38), BA: 144.14 (+2.33), AAPL: 122.68 (-0.70)
Illumina (ILMN) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - Wed Jul 22, 7:39AM CDT
The following Illumina (ILMN) conference call took place on July 21, 2015, 05:00 PM ET. This is a transcript of that earnings call:
ILMN: 215.38 (-2.44)
U.S. and Global Molecular Diagnostics in Infectious Disease Testing Market Report (Updated Edition)
M2 - Wed Jul 22, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tj5pr3/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing" report to their offering. This report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics - along with the development of microarray devices to measure analytes in the blood - has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. The purpose of this report is to describe the emerging field of molecular diagnostics in infectious disease testing. The infectious disease space is the most dominant and profitable sector of molecular diagnostics. Topics covered in this study include: - The existing and emerging technologies in the field - The U.S. and global market size for molecular diagnostic products - The profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - Biocartis - BioHelix Corporation (now part of Quidel) - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Great Basin Corporation - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - SACACE - Seegene - Siemens AG - SIRS-Lab - TrimGen - TrovaGene For more information visit http://www.researchandmarkets.com/research/tj5pr3/molecular
GNMK: 8.69 (-0.14), LIFE: 17.80 (-1.11), ABT: 51.00 (+0.06), MYGN: 33.21 (-0.49), AGMX: (), CPHD: 55.86 (-0.47), ILMN: 215.38 (-2.44), QGEN: 27.81 (+0.22), LMNX: 17.14 (-0.67)
Illumina Stock Dives As Q2 Earnings Beat, Sales Miss
at Investor's Business Daily - Tue Jul 21, 5:58PM CDT
Gene-sequencing giant Illumina beat analysts' Q2 earnings estimates Tuesday but missed on revenue for the first time in six years, sending shares down 9.5% in after-hours trading. Illumina (ILMN) said income excluding one-time items amounted to 80...
ILMN: 215.38 (-2.44)
Key Takeaways from Ilumina's (ILMN) Q2 Earnings - Stocks in the News
Maher Syed - Zacks Investment Research - Tue Jul 21, 5:07PM CDT
Why are Ilumina shares down 8% in after hour trading today?
ILMN: 215.38 (-2.44)
Illumina Inc.'s Q2 Results Fall Short
Keith Speights, The Motley Fool - Motley Fool - Tue Jul 21, 5:03PM CDT
Source: Illumina Judging from Illumina 's after-hours drop of nearly 11% on Tuesday before its partial recovery, you might think the genomic sequencing company reported horrible second quarter financial results. That wasn't really the case,...
ILMN: 215.38 (-2.44)
4 IBD 50 Stocks Poised To Bounce Back With Market
at Investor's Business Daily - Tue Jul 28, 3:13PM CDT
As the market bounces back after five straight sessions of losses, here's a look at four IBD 50 stocks that could bounce back after finding support at their moving averages: United Therapeutics (UTHR), Ellie Mae (ELLI), Epam Systems (EPAM) and...
ELLI: 70.65 (-0.96), UTHR: 165.31 (-0.65), ILMN: 215.38 (-2.44), EPAM: 74.46 (+1.78)
3 Signs That the Healthcare Stock Bubble Might Have Just Popped
George Budwell, The Motley Fool - Motley Fool - Mon Jul 27, 9:42AM CDT
Over the past five years or so, healthcare stocks have been absolutely trouncing the broader markets, leading many to call this unprecedented bull run a "bubble." A deeper look, though, reveals that most of this hypergrowth in the healthcare...
BIIB: 310.68 (-9.25), ILMN: 215.38 (-2.44), ABBV: 71.39 (+0.16)
Valeant, Starbucks Lead 5 IBD 50 Stocks Bucking Market
at Investor's Business Daily - Fri Jul 24, 6:14PM CDT
A handful of IBD 50 stocks got a boost last week, bucking overall market weakness, thanks to better-than-expected quarterly results. Illumina (ILMN), which makes genetic testing equipment, was among the few disappointments. It plunged 8% Wednesday...
VRX: 254.25 (-3.70), ELLI: 70.65 (-0.96), FB: 96.05 (+0.76), UHS: 141.69 (+0.32), UTHR: 165.31 (-0.65), ORLY: 239.78 (-1.17), EW: 151.25 (-4.55), ILMN: 215.38 (-2.44), MANH: 64.23 (-0.29), SBUX: 57.32 (+0.18), VDSI: 21.06 (-5.49), CRUS: 33.11 (-1.11), TASR: 31.18 (+0.40), AAPL: 122.67 (-0.71)
10.7% Return Seen to Date on SmarTrend Illumina Call (ILMN)
Comtex SmarTrend(R) - Wed Jul 22, 4:56PM CDT
SmarTrend identified an Uptrend for Illumina (NASDAQ:ILMN) on May 11th, 2015 at $196.42. In approximately 2 months, Illumina has returned 10.73% as of today's recent price of $217.49.
ILMN: 215.38 (-2.44)
Illumina Breaches Key Level On Q2 Sales Miss
at Investor's Business Daily - Wed Jul 22, 3:54PM CDT
Illumina (ILMN) surpassed second quarter earnings estimates late Tuesday but missed on revenue for the first time in six years. Analysts expected a beat-and-raise from the maker of gene sequencing systems, so its shares suffered in the stock market...
BIIB: 310.68 (-9.25), VRX: 254.25 (-3.70), DGX: 73.19 (+1.07), ILMN: 215.38 (-2.44), ABBV: 71.39 (+0.16), CELG: 132.79 (-2.63)
After Yesterday's Decline of 8.44%, Illumina Offers Investors Better Value
Comtex SmarTrend(R) - Wed Jul 22, 3:47PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $207.02 to a high of $220.00. Yesterday, the shares fell 8.4%, which took the trading range below the 3-day low of $230.00 on volume of 6.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 215.38 (-2.44)
Watch for Illumina to Potentially Rebound After Falling 8.44% Yesterday
Comtex SmarTrend(R) - Wed Jul 22, 3:47PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $207.02 to a high of $220.00. Yesterday, the shares fell 8.4%, which took the trading range below the 3-day low of $230.00 on volume of 6.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 215.38 (-2.44)
Apple and 3 Other Stocks with Major Price Changes Post-Earnings - Stocks in the News
Maher Syed - Zacks Investment Research - Wed Jul 22, 1:54PM CDT
The price reaction to each report is most volatile just after the earnings are announced. Trading the next day tends to bear some significant weight as well, though.
ISRG: 538.61 (-1.65), CMG: 737.72 (+6.94), ILMN: 215.38 (-2.44), AAPL: 122.67 (-0.71)
How to Trade 5 of the Market's Most Active Stocks
at The Street - Wed Jul 22, 1:40PM CDT
Here's a technical look at how to trade some of the highest-volume stocks on the market today.
KO: 40.60 (+0.05), XOM: 82.75 (+0.27), ILMN: 215.38 (-2.44), TSM: 21.92 (+0.04), MSFT: 46.72 (+1.38)
Comeback Efforts Lose Steam; Lithia Revs Higher
at Investor's Business Daily - Wed Jul 22, 11:03AM CDT
Stocks continued to trade in the red, with rebound efforts fading near Wednesday's halftime. The Nasdaq was off 0.8%, hurt by Apple (AAPL), which lost 5% on lighter-than-expected iPhone demand and a soft sales outlook. Intraday, the Nasdaq was down...
LAD: 117.34 (+4.75), ILMN: 215.38 (-2.44), MANH: 64.23 (-0.29), AAPL: 122.67 (-0.71), PII: 135.95 (-0.91)
Why Illumina Inc. Stock Sank Like a Stone Today
George Budwell, The Motley Fool - Motley Fool - Wed Jul 22, 10:58AM CDT
What's happening : Shares of the gene-sequencing company Illumina dropped by as much as 11% today on heavy volume following the release of its second-quarter results after the bell yesterday. For the quarter, Illumina posted $539 million in...
ILMN: 215.38 (-2.44)
Illumina (ILMN) Stock Falls After Reporting Earnings Results
at The Street - Wed Jul 22, 10:33AM CDT
Illumina (ILMN) shares are declining after the company reported its earnings results for the 2015 second quarter.
ILMN: 215.38 (-2.44)
Illumina Tops Q2 Earnings, Misses on Revenues; EPS View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 9:10AM CDT
Illumina's (ILMN) bottom line comfortably exceeded the Zacks Consensus Estimate, while the top line missed the same.
NLNK: 51.08 (-2.73), LGND: 104.20 (-1.64), ILMN: 215.38 (-2.44), AMAG: 64.83 (-1.40)
Downgrade Alert for Illumina (ILMN)
Comtex SmarTrend(R) - Wed Jul 22, 8:07AM CDT
Illumina (NASDAQ:ILMN) was downgraded from Buy to Neutral at Janney Montgomery today. The stock closed yesterday at $237.54 on volume of 2.3 million shares, above average daily volume of 1.3 million. In the past 52 weeks, shares of Illumina have traded between a low of $25.57 and a high of $242.37 and closed yesterday at $237.54, which is 829% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 1.3% while the 200-day MA has risen 0.6%.
ILMN: 215.38 (-2.44)
Stock Futures Down, Action Mixed; Apple, Vasco, Illumina Tumble
at Investor's Business Daily - Wed Jul 22, 8:04AM CDT
Stock futures veered unevenly lower on a heavy slate of earnings reports ahead of Wednesday's open. Dow futures were down 30.3 points below fair market value, but had pared early losses. Nasdaq 100 futures were down 62.4 points and sliding. S&P 500...
KO: 40.60 (+0.05), WHR: 178.17 (+1.45), VDSI: 21.06 (-5.49), SWKS: 94.07 (-1.61), ILMN: 215.38 (-2.44), CRUS: 33.11 (-1.11), HAWK: 44.53 (+0.41), MSFT: 46.72 (+1.38), BA: 144.14 (+2.33), AAPL: 122.68 (-0.70)
Illumina (ILMN) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - Wed Jul 22, 7:39AM CDT
The following Illumina (ILMN) conference call took place on July 21, 2015, 05:00 PM ET. This is a transcript of that earnings call:
ILMN: 215.38 (-2.44)
U.S. and Global Molecular Diagnostics in Infectious Disease Testing Market Report (Updated Edition)
M2 - Wed Jul 22, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tj5pr3/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing" report to their offering. This report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics - along with the development of microarray devices to measure analytes in the blood - has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. The purpose of this report is to describe the emerging field of molecular diagnostics in infectious disease testing. The infectious disease space is the most dominant and profitable sector of molecular diagnostics. Topics covered in this study include: - The existing and emerging technologies in the field - The U.S. and global market size for molecular diagnostic products - The profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - Biocartis - BioHelix Corporation (now part of Quidel) - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Great Basin Corporation - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - SACACE - Seegene - Siemens AG - SIRS-Lab - TrimGen - TrovaGene For more information visit http://www.researchandmarkets.com/research/tj5pr3/molecular
GNMK: 8.69 (-0.14), LIFE: 17.80 (-1.11), ABT: 51.00 (+0.06), MYGN: 33.21 (-0.49), AGMX: (), CPHD: 55.86 (-0.47), ILMN: 215.38 (-2.44), QGEN: 27.81 (+0.22), LMNX: 17.14 (-0.67)
Illumina Stock Dives As Q2 Earnings Beat, Sales Miss
at Investor's Business Daily - Tue Jul 21, 5:58PM CDT
Gene-sequencing giant Illumina beat analysts' Q2 earnings estimates Tuesday but missed on revenue for the first time in six years, sending shares down 9.5% in after-hours trading. Illumina (ILMN) said income excluding one-time items amounted to 80...
ILMN: 215.38 (-2.44)
Key Takeaways from Ilumina's (ILMN) Q2 Earnings - Stocks in the News
Maher Syed - Zacks Investment Research - Tue Jul 21, 5:07PM CDT
Why are Ilumina shares down 8% in after hour trading today?
ILMN: 215.38 (-2.44)
Illumina Inc.'s Q2 Results Fall Short
Keith Speights, The Motley Fool - Motley Fool - Tue Jul 21, 5:03PM CDT
Source: Illumina Judging from Illumina 's after-hours drop of nearly 11% on Tuesday before its partial recovery, you might think the genomic sequencing company reported horrible second quarter financial results. That wasn't really the case,...
ILMN: 215.38 (-2.44)
